Search

Your search keyword '"Lund, Lars H."' showing total 1,883 results
Start Over Author "Lund, Lars H."
1,883 results on '"Lund, Lars H."'

205. Data standards for heart failure : the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)

Author

Aktaa, Suleman, Batra, Gorav, Cleland, John G.F., Coats, Andrew, Lund, Lars H., McDonagh, Theresa, Rosano, Giuseppe, Seferovic, Peter, Vasko, Peter, Wallentin, Lars, Maggioni, Aldo P., Casadei, Barbara, and Gale, Chris P.

Subjects
Heart Failure, Kardiologi, Quality of care, Cardiology, Heart failure, Europe, Data standards, Variables, EuroHeart, Humans, Cardiac and Cardiovascular Systems, Registries, Data definitions, Cardiology and Cardiovascular Medicine, Randomized Controlled Trials as Topic, RC
Abstract

Standardized data definitions are essential for assessing the quality of care and patient outcomes in observational studies and randomized controlled trials. The European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart) project of the European Society of Cardiology (ESC) aims to create contemporary pan-European data standards for cardiovascular diseases, including heart failure (HF). We followed the EuroHeart methodology for cardiovascular data standard development. A Working Group including experts in HF registries, representatives from the Heart Failure Association of the ESC, and the EuroHeart was formed. Using Embase and Medline (2016–21), we conducted a systematic review of the literature on data standards, registries, and trials to identify variables pertinent to HF. A modified Delphi method was used to reach a consensus on the final set of variables. For each variable, the Working Group developed data definitions and agreed on whether it was mandatory (Level 1) or additional (Level 2). In total, 84 Level 1 and 79 Level 2 variables were selected for nine domains of HF care. These variables were reviewed by an international Reference Group with the Level 1 variables providing the dataset for registration of patients with HF on the EuroHeart IT platform. By means of a structured process and interaction with international stakeholders, harmonized data standards for HF have been developed. In the context of the EuroHeart, this will facilitate quality improvement, international observational research, registry-based randomized trials, and post-marketing surveillance of devices and pharmacotherapies across Europe.

Published
2022

207. Right Heart Failure Following Left Ventricular Device Implantation: Natural History, Risk Factors, and Outcomes: An Analysis of the STS INTERMACS Database

Author

Kapelios, Chris J., primary, Lund, Lars H., additional, Wever-Pinzon, Omar, additional, Selzman, Craig H., additional, Myers, Susan L., additional, Cantor, Ryan S., additional, Stehlik, Josef, additional, Chamogeorgakis, Themistocles, additional, McKellar, Stephen H., additional, Koliopoulou, Antigone, additional, Alharethi, Rami, additional, Kfoury, Abdallah G., additional, Bonios, Michael, additional, Adamopoulos, Stamatis, additional, Gilbert, Edward M., additional, Fang, James C., additional, Kirklin, James K., additional, and Drakos, Stavros G., additional

Published
2022
Full Text
View/download PDF

208. Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality

Author

Schrage, Benedikt, primary, Lund, Lars H., additional, Benson, Lina, additional, Dahlström, Ulf, additional, Shadman, Ramin, additional, Linde, Cecilia, additional, Braunschweig, Frieder, additional, Levy, Wayne C., additional, and Savarese, Gianluigi, additional

Published
2022
Full Text
View/download PDF

210. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

Aimo, Alberto, primary, Vergaro, Giuseppe, additional, González, Arantxa, additional, Barison, Andrea, additional, Lupón, Josep, additional, Delgado, Victoria, additional, Richards, A Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, Hülsmann, Martin, additional, Falcao‐Pires, Inês, additional, Díez, Javier, additional, Foo, Roger S.Y., additional, Chan, Mark Yan Yee, additional, Anene‐Nzelu, Chukwuemeka G., additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Belenkov, Yuri, additional, Ben Gal, Tuvia, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Januzzi, James L., additional, Jhund, Pardeep, additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Metra, Marco, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mueller, Christian, additional, Mullens, Wilfried, additional, Núñez, Julio, additional, Piepoli, Massimo F., additional, Rakisheva, Amina, additional, Ristić, Arsen D., additional, Rossignol, Patrick, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, Emdin, Michele, additional, and Bayes‐Genis, Antoni, additional

Published
2022
Full Text
View/download PDF

212. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

González, Arantxa, primary, Richards, A. Mark, additional, de Boer, Rudolf A., additional, Thum, Thomas, additional, Arfsten, Henrike, additional, Hülsmann, Martin, additional, Falcao‐Pires, Inês, additional, Díez, Javier, additional, Foo, Roger S.Y., additional, Chan, Mark Y., additional, Aimo, Alberto, additional, Anene‐Nzelu, Chukwuemeka G., additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Belenkov, Yuri, additional, Ben Gal, Tuvia, additional, Cohen‐Solal, Alain, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Delgado, Victoria, additional, Emdin, Michele, additional, Jankowska, Ewa A., additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Januzzi, James L., additional, Jhund, Pardeep S., additional, Lopatin, Yuri, additional, Lund, Lars H., additional, Metra, Marco, additional, Milicic, Davor, additional, Moura, Brenda, additional, Mueller, Christian, additional, Mullens, Wilfried, additional, Núñez, Julio, additional, Piepoli, Massimo F., additional, Rakisheva, Amina, additional, Ristić, Arsen D., additional, Rossignol, Patrick, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Volterrani, Maurizio, additional, Seferovic, Petar, additional, Rosano, Giuseppe, additional, Coats, Andrew J.S., additional, and Bayés‐Genís, Antoni, additional

Published
2022
Full Text
View/download PDF

213. Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction

Author

Savarese, Gianluigi, primary, Uijl, Alicia, additional, Ouwerkerk, Wouter, additional, Tromp, Jasper, additional, Anker, Stefan D., additional, Dickstein, Kenneth, additional, Hage, Camilla, additional, Lam, Carolyn S.P., additional, Lang, Chim C., additional, Metra, Marco, additional, Ng, Leong L., additional, Orsini, Nicola, additional, Samani, Nilesh J., additional, van Veldhuisen, Dirk J., additional, Cleland, John G.F., additional, Voors, Adriaan A., additional, and Lund, Lars H., additional

Published
2022
Full Text
View/download PDF

216. Cardiac Remodelling Part 1: From Cells and Tissues to Circulating Biomarkers:From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

Author

González, Arantxa, Richards, A Mark, Boer, Rudolf A, Thum, Thomas, Arfsten, Henrike, Hülsmann, Martin, Falcao‐Pires, Inês, Díez, Javier, Foo, Roger SY, Chan, Mark Yan Yee, Aimo, Alberto, Anene‐Nzelu, George C, Abdelhamid, Magdy, Adamopoulos, Stamatis, Anker, Stefan D, Belenkov, Yuri, Gal, Tuvia B, Cohen‐Solal, Alain, Böhm, Michael, Chioncel, Ovidiu, Delgado, Victoria, Emdin, Michele, Jankowska, Ewa A, Gustafsson, Finn, Hill, Loreena, Jaarsma, Tiny, Januzzi, James L, Jhund, Pardeep S, Lopatin, Yuri, Lund, Lars H, Metra, Marco, Milicic, Davor, Moura, Brenda, Mueller, Christian, Mullens, Wilfried, Núñez, Julio, Piepoli, Massimo F, Rakisheva, Amina, Ristic, Arsen, Rossignol, Patrick, Savarese, Gianluigi, Tocchetti, Carlo G, Van Linthout, Sophie, Volterrani, Maurizio, Seferovic, Petar, Rosano, Giuseppe, Coats, Andrew JS, and Bayes‐Genis, Antoni

Subjects
Tissue, Cells, Cardiology and Cardiovascular Medicine, Biomarkers, Remodeling
Abstract

Cardiac remodelling refers to changes in left ventricular (LV) structure and function over time, with a progressive deterioration that may lead to heart failure (HF) development (adverse remodelling) or vice versa a recovery in response to HF treatment. Adverse remodelling predicts a worse outcome, whilst reverse remodelling predicts a better prognosis. The geometry, systolic and diastolic function and electric activity of the left ventricle are affected, as well as the left atrium and on the long term even right heart chambers. At a cellular and molecular level, remodelling involves all components of cardiac tissue: cardiomyocytes, fibroblasts, endothelial cells and leukocytes. The molecular, cellular and histological signatures of remodelling may differ according to the cause and severity of cardiac damage, and clearly to the global trend toward worsening or recovery. These processes cannot be routinely evaluated through endomyocardial biopsies, but may be reflected by circulating levels of several biomarkers. Different classes of biomarkers (e.g., proteins, non-coding RNAs, metabolites and/or epigenetic modifications) and many biomarkers of each class might inform on some aspects on HF development, progression and long-term outcomes, but most have failed to enter clinical practice. This may be due to the biological complexity of remodelling, so that no single biomarker could provide great insight on remodelling when assessed alone. Another possible reason is a still incomplete understanding of the role of biomarkers in the pathophysiology of cardiac remodelling. Such role will be investigated in the first part of review paper on biomarkers of cardiac remodelling.

Published
2022

217. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Author

Zeppenfeld, Katja, Tfelt-Hansen, Jacob, de Riva, Marta, Winkel, Bo Gregers, Behr, Elijah R, Blom, Nico A, Charron, Philippe, Corrado, Domenico, Dagres, Nikolaos, de Chillou, Christian, Eckardt, Lars, Friede, Tim, Haugaa, Kristina H, Hocini, Mélèze, Lambiase, Pier D, Marijon, Eloi, Merino, Jose L, Peichl, Petr, Priori, Silvia G, Reichlin, Tobias, Schulz-Menger, Jeanette, Sticherling, Christian, Tzeis, Stylianos, Verstrael, Axel, Volterrani, Maurizio, Cikes, Maja, Kirchhof, Paulus, Abdelhamid, Magdy, Aboyans, Victor, Arbelo, Elena, Arribas, Fernando, Asteggiano, Riccardo, Basso, Cristina, Bauer, Axel, Bertaglia, Emanuele, Biering-Sørensen, Tor, Blomström-Lundqvist, Carina, Borger, Michael A, Čelutkienė, Jelena, Cosyns, Bernard, Falk, Volkmar, Fauchier, Laurent, Gorenek, Bulent, Halvorsen, Sigrun, Hatala, Robert, Heidbuchel, Hein, Kaab, Stefan, Konradi, Aleksandra, Koskinas, Konstantinos C, Kotecha, Dipak, Landmesser, Ulf, Lewis, Basil S, Linhart, Ales, Løchen, Maja-Lisa, Lund, Lars H, Metzner, Andreas, Mindham, Richard, Nielsen, Jens Cosedis, Norekvål, Tone M, Patten, Monica, Prescott, Eva, Rakisheva, Amina, Remme, Carol Ann, Roca-Luque, Ivo, Sarkozy, Andrea, Scherr, Daniel, Sitges, Marta, Touyz, Rhian M, Van Mieghem, Nicolas, Velagic, Vedran, Viskin, Sami, Volders, Paul G A, Pediatrics, Physiology, ACS - Heart failure & arrhythmias, Paediatric Cardiology, Cardiology, and APH - Methodology

Subjects
Genetic testing, Cardiac magnetic resonance, Sudden death, Arrhythmias, Cardiac, Ventricular tachycardia, Primary electrical disease, Guidelines, Recommendations, Chronic coronary artery disease, Risk calculator, Sudden cardiac death, Death, Sudden, Cardiac, Implantable cardioverter defibrillator, Ventricular arrhythmia, Humans, Catheter ablation, Anti-arrhythmic drugs, Ventricular fibrillation, Cardiology and Cardiovascular Medicine, 610 Medicine & health, Cardiomyopathies, Premature ventricular complex, Risk stratification
Published
2022

218. Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study

Author

Linde, Cecilia, Ekstrom, Mattias, Eriksson, Maria J., Maret, Eva, Wallen, Hakan, Lynga, Patrik, Weden, Ulla, Cabrera, Carin, Lofstrom, Ulrika, Stenudd, Jenny, Lund, Lars H., Persson, Bengt, Persson, Hans, and Hage, Camilla

Subjects
Heart Failure, Diastolic function, Kardiologi, Epidemiology, Stroke Volume, Heart failure, Preserved ejection fraction, Prognosis, Peptide Fragments, Ventricular Function, Left, Echocardiography, Natriuretic Peptide, Brain, Humans, Female, Cardiac and Cardiovascular Systems, Cardiology and Cardiovascular Medicine, Biomarkers
Abstract

Aim We present the baseline characteristics of the PREFERS Stockholm epidemiological study on the natural history and course of new onset heart failure (HF) aiming to improve phenotyping focusing on HF with preserved left ventricular ejection fraction (HFpEF) pathophysiology. Methods and results New onset HF patients diagnosed in hospital or at outpatient HF clinics were included at five Stockholm hospitals 2015-2018 and characterized by N-terminal pro brain natriuretic peptide (NT-proBNP), biomarkers, echocardiography, and cardiac magnetic resonance imaging (subset). HFpEF [left ventricular ejection fraction (LVEF) >= 50%) was compared with HF with mildly reduced LVEF (HFmrEF; LVEF 41-49%) and with HF with reduced LVEF (HFrEF; LVEF = 14 was present in 26% of HFpEF vs. 32% of HFrEF (P = 0.017) and left atrial volume index > 34 mL/m(2) in 57% vs. 61% (P = 0.040). HFmrEF patients were intermediary between HFpEF and HFrEF for LV mass, LV volumes, and RV volumes but had the highest proportion of left ventricular hypertrophy and the lowest proportion of elevated E/e. Conclusions Phenotype data in new onset HF patients recruited in a broad clinical setting showed that 25% had HFpEF, were older, more often women, and had greater comorbidity burden. PREFERS is well suited to further explore biomarker and imaging components of HFpEF pathophysiology and may contribute to the emerging knowledge of HF epidemiology.

Published
2022

225. Epigenetic modulators link mitochondrial redox homeostasis to cardiac function

Author

Elbeck, Zaher, primary, Hossain, Mohammad Bakhtiar, additional, Siga, Humam, additional, Oskolkov, Nikolay, additional, Karlsson, Fredrik, additional, Lindgren, Julia, additional, Walentinsson, Anna, additional, Remedios, Cristobal Dos, additional, Koppenhöfer, Dominique, additional, Jarvis, Rebecca, additional, Bürli, Roland, additional, Jamier, Tanguy, additional, Franssen, Elske, additional, Firth, Mike, additional, Degasperi, Andrea, additional, Bendtsen, Claus, additional, Dudek, Jan, additional, Kohlhaas, Michael, additional, Nickel, Alexander G., additional, Lund, Lars H., additional, Maack, Christoph, additional, Végvári, Ákos, additional, and Betsholtz, Christer, additional

Published
2022
Full Text
View/download PDF

230. European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology

Author

Aktaa, Suleman, primary, Polovina, Marija, additional, Rosano, Giuseppe, additional, Abdin, Amr, additional, Anguita, Manuel, additional, Lainscak, Mitja, additional, Lund, Lars H., additional, McDonagh, Theresa, additional, Metra, Marco, additional, Mindham, Richard, additional, Piepoli, Massimo, additional, Störk, Stefan, additional, Tokmakova, Mariya P., additional, Seferović, Petar, additional, Gale, Chris P., additional, and Coats, Andrew J.S., additional

Published
2022
Full Text
View/download PDF

231. Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme

Author

Seferovic, Petar M., Piepoli, Massimo F., Lopatin, Yuri, Jankowska, Ewa, Polovina, Marija, Anguita-Sanchez, Manuel, Stoerk, Stefan, Lainscak, Mitja, Milicic, Davor, Milinkovic, Ivan, Filippatos, Gerasimos, Coats, Andrew J. S., Anker, Stefan, Backs, Johannes, Bauersachs, Johann, Ben Gal, Tuvia, de Boer, Rudolf A., Doehner, Wolfram, Celutkiene, Jelena, Chioncel, Ovidiu, Heymans, Stephane, Hill, Loreena, Jaarsma, Tiny, Lund, Lars H., Lyon, Alexander R., Metra, Marco, Moura, Brenda, Mueller, Cristian, Mullens, Wilfried, Ponikowski, Piotr, Rosano, Giuseppe, Ruschitzka, Frank, Thum, Thomas, Volterrani, Maurizio, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H02 Cardiomyopathy, and Cardiovascular Centre (CVC)

Subjects
medicine.medical_specialty, Cardiology, Heart failure, Audit, ORGANIZATION, 030204 cardiovascular system & hematology, Accreditation, DISEASE MANAGEMENT PROGRAMS, 03 medical and health sciences, 0302 clinical medicine, Multidisciplinary approach, Internal medicine, Intensive care, Health care, Disease management, Medicine, Humans, Disease management (health), Human resources, Quality of Health Care, Heart Failure, Patient, business.industry, Research, Multidisciplinary care, Quality of care, ADMISSION, 3. Good health, CLINICS, Europe, SURVIVAL, Cardiology and Cardiovascular Medicine, business, Hospital accreditation, Editorial Comment, INTERVENTION, MULTIDISCIPLINARY
Abstract

Heart failure (HF) is the major contributor to cardiovascular morbidity and mortality. Given its rising prevalence, the costs of HF care can be expected to increase. Multidisciplinary management of HF can improve quality of care and survival. However, specialized HF programmes are not widely available in most European countries. These circumstances underlie the suggestion of the Heart Failure Association (HFA)of the European Society of Cardiology (ESC) for the development of quality of care centres (QCCs). These are defined as health care institutions that provide multidisciplinary HF management at all levels of care (primary, secondary and tertiary), are accredited by the HFA/ESC and are implemented into existing health care systems. Their major goals are to unify and improve the quality of HF care, and to promote collaboration in education and research activities. Three types of QCC are suggested: community QCCs (primary care facilities able to provide non-invasive assessment and optimal therapy); specialized QCCs (district hospitals with intensive care units, able to provide cardiac catheterization and device implantation services), and advanced QCCs (national reference centres able to deliver advanced and innovative HF care and research). QCC accreditation will require compliance with general and specific HFA/ESC accreditation standards. General requirements include confirmation of the centre's existence, commitment to QCC implementation, and collaboration with other QCCs. Specific requirements include validation of the centre's level of care, service portfolio, facilities and equipment, management, human resources, process measures, quality indicators and outcome measures. Audit and recertification at 4-6-year intervals are also required. The implementation of QCCs will evolve gradually, following a pilot phase in selected countries. The present document summarizes the definition, major goals, development, classification and crucial aspects of the accreditation process of the HFA/ESC QCC Programme.

Published
2020

232. Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

Author

Butler, Javed, primary, Anker, Stefan D., additional, Siddiqi, Tariq Jamal, additional, Coats, Andrew J.S., additional, Dorigotti, Fabio, additional, Filippatos, Gerasimos, additional, Friede, Tim, additional, Göhring, Udo‐Michael, additional, Kosiborod, Mikhail N., additional, Lund, Lars H., additional, Metra, Marco, additional, Moreno Quinn, Carol, additional, Piña, Ileana L., additional, Pinto, Fausto J., additional, Rossignol, Patrick, additional, Szecsödy, Peter, additional, Van Der Meer, Peter, additional, Weir, Matthew, additional, and Pitt, Bertram, additional

Published
2021
Full Text
View/download PDF

233. Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology

Author

Coats, Andrew J S, primary, Heymans, Stephane, additional, Farmakis, Dimitrios, additional, Anker, Stefan D, additional, Backs, Johannes, additional, Bauersachs, Johann, additional, de Boer, Rudolf A, additional, Čelutkienė, Jelena, additional, Cleland, John G F, additional, Dobrev, Dobromir, additional, van Gelder, Isabelle C, additional, von Haehling, Stephan, additional, Hindricks, Gerhard, additional, Jankowska, Ewa, additional, Kotecha, Dipak, additional, van Laake, Linda W, additional, Lainscak, Mitja, additional, Lund, Lars H, additional, Lunde, Ida Gjervold, additional, Lyon, Alexander R, additional, Manouras, Aristomenis, additional, Miličić, Davor, additional, Mueller, Christian, additional, Polovina, Marija, additional, Ponikowski, Piotr, additional, Rosano, Giuseppe, additional, Seferović, Petar M, additional, Tschöpe, Carsten, additional, Wachter, Rolf, additional, and Ruschitzka, Frank, additional

Published
2021
Full Text
View/download PDF

234. 297 Echocardiographic biventricular coupling index to predict pre-capillary pulmonary hypertension

Author

Albani, Stefano, primary, Stolfo, Davide, additional, Venkateshvaran, Ashwin, additional, Chubuchny, Vladyslav, additional, De Scordilli, Marco, additional, Biondi, Federico, additional, De Luca, Antonio, additional, Pinamonti, Bruno, additional, Lo Giudice, Francesco, additional, Pasanisi, Emilio M, additional, Petersen, Christina, additional, Airò, Edoardo, additional, Bauleo, Carolina, additional, Ciardetti, Marco, additional, Coaceani, Michele, additional, Formnichi, Bruno, additional, Spiesshoefer, Jens, additional, Savarese, Gianluigi, additional, Lund, Lars H, additional, Emdin, Michele, additional, Sinagra, Gianfranco, additional, Manouras, Aristomenis, additional, and Giannoni, Alberto, additional

Published
2021
Full Text
View/download PDF

238. Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry

Author

Kapelios, Chris J., primary, Canepa, Marco, additional, Benson, Lina, additional, Hage, Camilla, additional, Thorvaldsen, Tonje, additional, Dahlström, Ulf, additional, Savarese, Gianluigi, additional, and Lund, Lars H., additional

Published
2021
Full Text
View/download PDF

239. COVID‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology

Author

Rosano, Giuseppe, primary, Jankowska, Ewa A., additional, Ray, Robin, additional, Metra, Marco, additional, Abdelhamid, Magdy, additional, Adamopoulos, Stamatis, additional, Anker, Stefan D., additional, Bayes‐Genis, Antoni, additional, Belenkov, Yury, additional, Ben Gal, Tuvia, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Cohen‐Solal, Alain, additional, Farmakis, Dimitrios, additional, Filippatos, Gerasimos, additional, González, Arantxa, additional, Gustafsson, Finn, additional, Hill, Loreena, additional, Jaarsma, Tiny, additional, Jouhra, Fadi, additional, Lainscak, Mitja, additional, Lambrinou, Ekaterini, additional, Lopatin, Yury, additional, Lund, Lars H., additional, Milicic, Davor, additional, Moura, Brenda, additional, Mullens, Wilfried, additional, Piepoli, Massimo F., additional, Ponikowski, Piotr, additional, Rakisheva, Amina, additional, Ristic, Arsen, additional, Savarese, Gianluigi, additional, Seferovic, Petar, additional, Senni, Michele, additional, Thum, Thomas, additional, Tocchetti, Carlo G., additional, Van Linthout, Sophie, additional, Volterrani, Maurizio, additional, and Coats, Andrew J.S., additional

Published
2021
Full Text
View/download PDF

240. ‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor

Author

Abdin, Amr, primary, Anker, Stefan D., additional, Butler, Javed, additional, Coats, Andrew J. Stewart, additional, Kindermann, Ingrid, additional, Lainscak, Mitja, additional, Lund, Lars H., additional, Metra, Marco, additional, Mullens, Wilfried, additional, Rosano, Giuseppe, additional, Slawik, Jonathan, additional, Wintrich, Jan, additional, and Böhm, Michael, additional

Published
2021
Full Text
View/download PDF

241. Generalizability of randomized controlled trials in heart failure with reduced ejection fraction

Author

Lim, Yvonne Mei Fong, primary, Molnar, Megan, additional, Vaartjes, Ilonca, additional, Savarese, Gianluigi, additional, Eijkemans, Marinus J C, additional, Uijl, Alicia, additional, Vradi, Eleni, additional, Suzart-Woischnik, Kiliana, additional, Brugts, Jasper J, additional, Brunner-La Rocca, Hans-Peter, additional, Blanc-Guillemaud, Vanessa, additional, Couvelard, Fabrice, additional, Baudier, Claire, additional, Dyszynski, Tomasz, additional, Waechter, Sandra, additional, Lund, Lars H, additional, Hoes, Arno W, additional, Tyl, Benoit, additional, Asselbergs, Folkert W, additional, Gerlinger, Christoph, additional, Grobbee, Diederick E, additional, Cronin, Maureen, additional, and Koudstaal, Stefan, additional

Published
2021
Full Text
View/download PDF

243. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology

Author

Mullens, Wilfried, Auricchio, Angelo, Martens, Pieter, Witte, Klaus, Cowie, Martin R., Delgado, Victoria, Dickstein, Kenneth, Linde, Cecilia, Vernooy, Kevin, Leyva, Francisco, Bauersachs, Johann, Israel, Carsten W., Lund, Lars H., Donal, Erwan, Boriani, Giuseppe, Jaarsma, Tiny, Berruezo, Antonio, Traykov, Vassil, Yousef, Zaheer, Kalarus, Zbigniew, Cosedis Nielsen, Jens, Steffel, Jan, Vardas, Panos, Coats, Andrew, Seferovic, Petar, Edvardsen, Thor, Heidbüchel, Hein, Ruschitzka, Frank, Leclercq, Christophe, University of Zurich, Mullens, Wilfried, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H06 Electro mechanics, and RS: Carim - H01 Clinical atrial fibrillation

Subjects
genetic structures, IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Heart failure, 610 Medicine & health, Health Services Misuse, 2705 Cardiology and Cardiovascular Medicine, 2737 Physiology (medical), LONG-TERM OUTCOMES, Disease management, Humans, Disease modification, PERMANENT ATRIAL-FIBRILLATION, ATRIOVENTRICULAR JUNCTION ABLATION, Referral and Consultation, EXPERT CONSENSUS STATEMENT, Outcome, Cardiac resynchronization therapy, Implementation, Care pathways, Disease Modification, Response, Utilization, ANGIOTENSIN-NEPRILYSIN INHIBITION, NONSUSTAINED VENTRICULAR-TACHYCARDIA, 2016 ESC GUIDELINES, Treatment Outcome, Critical Pathways, Quality of Life, 10209 Clinic for Cardiology, Human medicine, REDUCED EJECTION FRACTION, BUNDLE-BRANCH BLOCK
Abstract

Contains fulltext : 235382.pdf (Publisher’s version ) (Open Access) Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart failure with reduced ejection fraction and leads to improved quality of life, reductions in heart failure hospitalization rates and all-cause mortality. Nevertheless, up to two-thirds of eligible patients are not referred for CRT. Furthermore, post-implantation follow-up is often fragmented and suboptimal, hampering the potential maximal treatment effect. This joint position statement from three European Society of Cardiology Associations, Heart Failure Association (HFA), European Heart Rhythm Association (EHRA) and European Association of Cardiovascular Imaging (EACVI), focuses on optimized implementation of CRT. We offer theoretical and practical strategies to achieve more comprehensive CRT referral and post-procedural care by focusing on four actionable domains: (i) overcoming CRT under-utilization, (ii) better understanding of pre-implant characteristics, (iii) abandoning the term 'non-response' and replacing this by the concept of disease modification, and (iv) implementing a dedicated post-implant CRT care pathway.

Published
2021

248. Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry.

Author

Maggioni, Aldo P., Clark, Andrew L., Barrios, Vivencio, Damy, Thibaud, Drozdz, Jaroslaw, Fonseca, Candida, Lund, Lars H., Kalus, Stefanie, Ferber, Philippe C., Hussain, Rizwan I., Koch, Cornelia, and Zeymer, Uwe

Subjects
HEART failure, ENTRESTO, VENTRICULAR ejection fraction, VALSARTAN, OUTPATIENTS, PHYSICIANS
Abstract

Aims: ARIADNE aimed to assess the association between effects of sacubitril/valsartan and no sacubitril/valsartan treatment and clinical characteristics, functional capacity, and clinical outcomes (cause‐specific mortality and hospitalizations) in outpatients with heart failure (HF) with reduced ejection fraction (HFrEF). Methods: ARIADNE was a prospective European registry of 9069 patients with HFrEF treated by office‐based cardiologists or selected primary care physicians. Of the 8787 eligible for analysis, 4173 patients were on conventional HF treatment (non‐S/V group), whereas 4614 patients were either on sacubitril/valsartan treatment at enrolment or started sacubitril/valsartan within 1 month of enrolment (S/V group). We also generated a restricted analysis set (rS/V) including only those 2108 patients who started sacubitril/valsartan treatment within the month prior to or after enrolment. Results: At the baseline, average age of patients enrolled in the study was 68 years, and 23.9% (2099/8787) were female. At the baseline, the proportions of patients with New York Heart Association (NYHA) Class III symptoms were 30.9 (1288/4173), 42.8 (1974/4614), and 48.2% (1015/2108), in non‐S/V, S/V, and rS/V groups, respectively. After 12 months of treatment, the proportion of patients with NYHA Class III at baseline who improved to Class II was 32.0% (290/907) in the non‐S/V group vs. 46.3% (648/1399) in S/V group and 48.7% (349/717) in rS/V group. The overall mortality rate was 5.0 per 100 patient‐years. Rates of HF hospitalizations were high (20.9, 20.3, and 21.2 per 100 patient‐years in the non‐S/V, S/V, and rS/V groups, respectively). Emergency room visits without hospitalization occurred in 3.9, 3.2, and 3.9% of patients in the non‐S/V, S/V, and rS/V groups, respectively. Conclusions: This large HFrEF European registry provides a contemporary outcome profile of outpatients with HFrEF treated with or without sacubitril/valsartan. In a real‐world setting, sacubitril/valsartan was associated with an improvement of symptoms in patients with HFrEF compared with the conventional HFrEF treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

249. Citrullination is linked to reduced Ca2+ sensitivity in hearts of a murine model of rheumatoid arthritis.

Author

Pironti, Gianluigi, Gastaldello, Stefano, Rassier, Dilson E., Lanner, Johanna T., Carlström, Mattias, Lund, Lars H., Westerblad, Håkan, Yamada, Takashi, and Andersson, Daniel C.

Subjects
RHEUMATOID arthritis, POST-translational modification, COLLAGEN-induced arthritis, CALCIUM ions
Abstract

Aims: Cardiac contractile dysfunction is prevalent in rheumatoid arthritis (RA), with an increased risk for heart failure. A hallmark of RA has increased levels of peptidyl arginine deaminases (PAD) that convert arginine to citrulline leading to ubiquitous citrullination, including in the heart. We aimed to investigate whether PAD‐dependent citrullination in the heart was linked to contractile function in a mouse model of RA during the acute inflammatory phase. Methods: We used hearts from the collagen‐induced arthritis (CIA) mice, with overt arthritis, and control mice to analyze cardiomyocyte Ca2+ handling and fractional shortening, the force‐Ca2+ relationship in isolated myofibrils, the levels of PAD, protein post‐translational modifications, and Ca2+ handling protein. Then, we used an in vitro model to investigate the role of TNF‐α in the PAD‐mediated citrullination of proteins in cardiomyocytes. Results: Cardiomyocytes from CIA mice displayed larger Ca2+ transients than controls, whereas cell shortening was similar in the two groups. Myofibrils from CIA hearts required higher [Ca2+] to reach 50% of maximum shortening, ie Ca2+ sensitivity was lower. This was associated with increased PAD2 expression and α‐actin citrullination. TNF‐α increased PAD‐mediated citrullination which was blocked by pre‐treatment with the PAD inhibitor 2‐chloroacetamide. Conclusion: Using a mouse RA model we found evidence of impaired cardiac contractile function linked to reduced Ca2+ sensitivity, increased expression of PAD2, and citrullination of α‐actin, which was triggered by TNF‐α. This provides molecular and physiological evidence for acquired cardiomyopathy and a potential mechanism for RA‐associated heart failure. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results